304 related articles for article (PubMed ID: 20705936)
1. Cancer biomarkers: can we turn recent failures into success?
Diamandis EP
J Natl Cancer Inst; 2010 Oct; 102(19):1462-7. PubMed ID: 20705936
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in ovarian cancer screening.
Menon U; Jacobs IJ
Curr Opin Obstet Gynecol; 2000 Feb; 12(1):39-42. PubMed ID: 10752515
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for the early detection of cancer: an inflammatory concept.
Roy HK; Khandekar JD
Arch Intern Med; 2007 Sep; 167(17):1822-4. PubMed ID: 17893302
[No Abstract] [Full Text] [Related]
4. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.
Lan Z; Fu D; Yu X; Xi M
Fam Cancer; 2016 Apr; 15(2):221-30. PubMed ID: 26458935
[TBL] [Abstract][Full Text] [Related]
5. Limitations to the use of the CA-125 antigen level in ovarian cancer.
Markman M
Curr Oncol Rep; 2003 Jul; 5(4):263-4. PubMed ID: 12781066
[No Abstract] [Full Text] [Related]
6. Discovery and application of protein biomarkers for ovarian cancer.
Gagnon A; Ye B
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
[TBL] [Abstract][Full Text] [Related]
7. The potential and problems of screening for ovarian cancer.
Yokoyama Y; Higuchi T; Mizunuma H
Eur J Gynaecol Oncol; 2005; 26(3):241-3. PubMed ID: 15991520
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of tumour markers in the management of ovarian cancer.
Rustin GJ
Ann Clin Biochem; 1996 Jul; 33 ( Pt 4)():284-9. PubMed ID: 8836386
[No Abstract] [Full Text] [Related]
9. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
[TBL] [Abstract][Full Text] [Related]
10. Status of tumor markers in ovarian cancer screening.
Bast RC
J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
[TBL] [Abstract][Full Text] [Related]
11. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
Diamandis EP
BMC Med; 2012 Aug; 10():87. PubMed ID: 22876833
[TBL] [Abstract][Full Text] [Related]
12. Improving the biomarker pipeline to develop and evaluate cancer screening tests.
Baker SG
J Natl Cancer Inst; 2009 Aug; 101(16):1116-9. PubMed ID: 19574417
[TBL] [Abstract][Full Text] [Related]
13. Designing early detection programs for ovarian cancer.
Hartge P
J Natl Cancer Inst; 2010 Jan; 102(1):3-4. PubMed ID: 20042718
[No Abstract] [Full Text] [Related]
14. Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.
Lutz AM; Willmann JK; Cochran FV; Ray P; Gambhir SS
PLoS Med; 2008 Aug; 5(8):e170. PubMed ID: 18715113
[TBL] [Abstract][Full Text] [Related]
15. Cancer: Missing the mark.
Buchen L
Nature; 2011 Mar; 471(7339):428-32. PubMed ID: 21430749
[No Abstract] [Full Text] [Related]
16. [Challenge of evidence-based medicine: sense and non-sense of diagnostic tests in gynecology].
Sehouli J; Stengel D; Hindenburg J; Camara O; Porzsolt F; Lichtenegger W;
Zentralbl Gynakol; 2001 Mar; 123(3):127-31. PubMed ID: 11340951
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
Mrochem J; Sodowski K; Deja R; Walaszek-Gruszka A; Wojcieszek A; Kołosza Z; Chmura A; Czernik E; Masłyk B; Bartnik W; Cnota W
Ginekol Pol; 2008 Apr; 79(4):271-5. PubMed ID: 18592865
[TBL] [Abstract][Full Text] [Related]
18. Early stage detection and screening of ovarian cancer: A research opportunity and significant challenge for biosensor technology.
Franier B; Thompson M
Biosens Bioelectron; 2019 Jun; 135():71-81. PubMed ID: 31003031
[TBL] [Abstract][Full Text] [Related]
19. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis.
Shariat SF; Scherr DS; Gupta A; Bianco FJ; Karakiewicz PI; Zeltser IS; Samadi DB; Akhavan A
Arch Esp Urol; 2011 Oct; 64(8):681-94. PubMed ID: 22052751
[TBL] [Abstract][Full Text] [Related]
20. Early prostate cancer antigen-2: a controversial prostate cancer biomarker?
Diamandis EP
Clin Chem; 2010 Apr; 56(4):542-4. PubMed ID: 20167690
[No Abstract] [Full Text] [Related]
[Next] [New Search]
